Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135508057> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W3135508057 endingPage "144" @default.
- W3135508057 startingPage "144" @default.
- W3135508057 abstract "144 Background: We have recently demonstrated that a salvage therapy with carboplatin plus weekly docetaxel is effective in docetaxel-refractory prostate cancer (PC) and interferes with testosterone biosynthesis (Reuter et al.; Oncol Res & Treat. 2018, 41 (suppl.1): p.10). In this study, the impact of docetaxel monotherapy on free and total testosterone serum levels (fT, TT) and the prognostic role of fT and TT were analyzed in mPC patients. Methods: 62 consecutive mPC patients were treated with at least two cycles of docetaxel (75 mg/m2 q3w; 50 mg/m2 q2w, or 35 mg/m2 q1w) until disease progression, occurrence of intolerable adverse effects or completion of the planned cycle number. Efficacy measures were done following PCWG2 recommendations. FT and TT were measured before and during chemotherapy. Results: At the current analysis (August 31, 2020), the median follow-up time was 21.2 months. Response of prostate-specific antigen (PSAR; ≥50% PSA reduction) was observed in 42/62 (67.7%) and 12/36 (33.3%) patients with measurable disease exhibited a partial remission (PR). Median progression-free survival (PFS) for all patients was 8.1 months (CI 95% 3.6, 12.5) and median overall survival (OS) was 25.7 months (CI 95% 19.4, 32.1). The most common reversible grade 3/4 toxicity was leukopenia/neutropenia (29/33.9%). Median fT and TT serum levels were reduced below the detection limit during docetaxel treatment (fT: from 0.34 pg/mL to < 0.01 pg/mL and TT: from 0.12 to < 0.05 ng/mL, respectively). Multivariate Cox regression analyses identified PSAR > 50%, fT reduction of 100% and number of organs involved as independent prognostic risk factors for PFS. Furthermore, fT reduction of 100% and FT nadir values < 0.01 pg/mL were independent prognostic risk factors for OS (p < 0.05). Conclusions: These data demonstrate that fT is an important prognostic factor for PFS and OS in mPC patients." @default.
- W3135508057 created "2021-03-15" @default.
- W3135508057 creator A5011083669 @default.
- W3135508057 creator A5011923291 @default.
- W3135508057 creator A5026803534 @default.
- W3135508057 creator A5062310799 @default.
- W3135508057 creator A5081076272 @default.
- W3135508057 date "2021-02-20" @default.
- W3135508057 modified "2023-09-23" @default.
- W3135508057 title "Prognostic role of docetaxel-induced reduction of free testosterone serum levels in metastatic prostate cancer patients." @default.
- W3135508057 doi "https://doi.org/10.1200/jco.2021.39.6_suppl.144" @default.
- W3135508057 hasPublicationYear "2021" @default.
- W3135508057 type Work @default.
- W3135508057 sameAs 3135508057 @default.
- W3135508057 citedByCount "0" @default.
- W3135508057 crossrefType "journal-article" @default.
- W3135508057 hasAuthorship W3135508057A5011083669 @default.
- W3135508057 hasAuthorship W3135508057A5011923291 @default.
- W3135508057 hasAuthorship W3135508057A5026803534 @default.
- W3135508057 hasAuthorship W3135508057A5062310799 @default.
- W3135508057 hasAuthorship W3135508057A5081076272 @default.
- W3135508057 hasConcept C121608353 @default.
- W3135508057 hasConcept C126322002 @default.
- W3135508057 hasConcept C126894567 @default.
- W3135508057 hasConcept C143998085 @default.
- W3135508057 hasConcept C2776694085 @default.
- W3135508057 hasConcept C2777063308 @default.
- W3135508057 hasConcept C2778850193 @default.
- W3135508057 hasConcept C2780192828 @default.
- W3135508057 hasConcept C2780201970 @default.
- W3135508057 hasConcept C2780873365 @default.
- W3135508057 hasConcept C2781190966 @default.
- W3135508057 hasConcept C2781406297 @default.
- W3135508057 hasConcept C2994223898 @default.
- W3135508057 hasConcept C71924100 @default.
- W3135508057 hasConcept C90924648 @default.
- W3135508057 hasConceptScore W3135508057C121608353 @default.
- W3135508057 hasConceptScore W3135508057C126322002 @default.
- W3135508057 hasConceptScore W3135508057C126894567 @default.
- W3135508057 hasConceptScore W3135508057C143998085 @default.
- W3135508057 hasConceptScore W3135508057C2776694085 @default.
- W3135508057 hasConceptScore W3135508057C2777063308 @default.
- W3135508057 hasConceptScore W3135508057C2778850193 @default.
- W3135508057 hasConceptScore W3135508057C2780192828 @default.
- W3135508057 hasConceptScore W3135508057C2780201970 @default.
- W3135508057 hasConceptScore W3135508057C2780873365 @default.
- W3135508057 hasConceptScore W3135508057C2781190966 @default.
- W3135508057 hasConceptScore W3135508057C2781406297 @default.
- W3135508057 hasConceptScore W3135508057C2994223898 @default.
- W3135508057 hasConceptScore W3135508057C71924100 @default.
- W3135508057 hasConceptScore W3135508057C90924648 @default.
- W3135508057 hasIssue "6_suppl" @default.
- W3135508057 hasLocation W31355080571 @default.
- W3135508057 hasOpenAccess W3135508057 @default.
- W3135508057 hasPrimaryLocation W31355080571 @default.
- W3135508057 hasRelatedWork W1495623746 @default.
- W3135508057 hasRelatedWork W1542568406 @default.
- W3135508057 hasRelatedWork W1975239262 @default.
- W3135508057 hasRelatedWork W2010765098 @default.
- W3135508057 hasRelatedWork W2106964779 @default.
- W3135508057 hasRelatedWork W2155169688 @default.
- W3135508057 hasRelatedWork W2253772357 @default.
- W3135508057 hasRelatedWork W2299690226 @default.
- W3135508057 hasRelatedWork W2977409384 @default.
- W3135508057 hasRelatedWork W3135508057 @default.
- W3135508057 hasVolume "39" @default.
- W3135508057 isParatext "false" @default.
- W3135508057 isRetracted "false" @default.
- W3135508057 magId "3135508057" @default.
- W3135508057 workType "article" @default.